title: G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day.
abstract: G-CSF is routinely administered after autologous bone marrow or peripheral blood progenitor cell transplantation to enhance neutrophil engraftment. However, many different doses of G-CSF have been described with no clear consensus on the most cost-effective dose. We performed a prospective randomized trial examining the efficacy of three different doses of G-CSF post-autologous transplant (5, 10, or 16 micrograms/kg/day). Fifty-seven consecutive patients with breast cancer (n = 30), non-Hodgkin's lymphoma (n = 16), Hodgkin's disease (n = 6), multiple myeloma (n = 2), acute leukemia (n = 2), and testicular cancer (n = 1) were randomized, with 19 patients enrolled in each of the three treatment groups. All patients underwent a high-dose chemotherapy preparative regimen and received an autologous peripheral blood progenitor cell (PBPC) transplant (without bone marrow), with G-CSF beginning on day 0. There was no difference in time to neutrophil engraftment among the three treatment groups (mean 10.2 to 10.8 days). There is a trend towards earlier platelet engraftment in the patient group receiving 5 microgram/kg/day of G-CSF. The total cost of G-CSF by dose group was $2900, $4400, and $6500 per patient. We conclude that there was no advantage to the use of higher doses of G-CSF after autologous transplantation, and that lower doses are associated with lower costs.
authors.affiliation: Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Ohio 44195, USA.
authors.forename: B
authors.initials: B
authors.lastname: Bolwell
authors.forename: M
authors.initials: M
authors.lastname: Goormastic
authors.forename: R
authors.initials: R
authors.lastname: Dannley
authors.forename: S
authors.initials: S
authors.lastname: Andresen
authors.forename: B
authors.initials: B
authors.lastname: Overmoyer
authors.forename: Z
authors.initials: Z
authors.lastname: Mendez
authors.forename: M
authors.initials: M
authors.lastname: Kalaycioglu
authors.forename: D
authors.initials: D
authors.lastname: DeMars
authors.forename: K
authors.initials: K
authors.lastname: Wise
authors.forename: B
authors.initials: B
authors.lastname: Pohlman
mesh_terms: D000328:Adult; D003365:Costs and Cost Analysis; D005260:Female; D006085:Graft Survival / Q000187:drug effects; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000191:economics; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014182:Transplantation, Autologous
chemical_list: D016179:Granulocyte Colony-Stimulating Factor